Total submissions: 4
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV002047423 | SCV002109291 | uncertain significance | not provided | 2024-01-07 | criteria provided, single submitter | clinical testing | This sequence change replaces glutamic acid, which is acidic and polar, with lysine, which is basic and polar, at codon 618 of the LZTR1 protein (p.Glu618Lys). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This variant has not been reported in the literature in individuals affected with LZTR1-related conditions. ClinVar contains an entry for this variant (Variation ID: 1352204). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt LZTR1 protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
| Ambry Genetics | RCV002406923 | SCV002716510 | uncertain significance | Hereditary cancer-predisposing syndrome; Cardiovascular phenotype | 2022-11-15 | criteria provided, single submitter | clinical testing | The p.E618K variant (also known as c.1852G>A), located in coding exon 16 of the LZTR1 gene, results from a G to A substitution at nucleotide position 1852. The glutamic acid at codon 618 is replaced by lysine, an amino acid with similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
| Baylor Genetics | RCV003470953 | SCV004191197 | uncertain significance | Schwannomatosis 2 | 2023-10-26 | criteria provided, single submitter | clinical testing | |
| Mayo Clinic Laboratories, |
RCV002047423 | SCV005410201 | uncertain significance | not provided | 2024-06-20 | criteria provided, single submitter | clinical testing |